NEPH (Nephros Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by NEPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Arthur H Amron | Director | A | — | — |
| 2026-03-25 | Robert R. Jr. Banks | President and CEO | M | — | — |
| 2026-03-25 | Judy Krandel | Chief Financial Officer | M | — | — |
| 2026-03-18 | Arthur H Amron | Director | A | — | — |
| 2026-03-18 | Judy Krandel | Chief Financial Officer | A | — | — |
| 2025-11-13 | Lisa Marie Nettis | Director | A | — | — |
| 2025-11-13 | Oliver J. Spandow | Director | A | — | — |
| 2025-11-13 | Arthur H Amron | Director | A | — | — |
| 2025-08-13 | Lisa Marie Nettis | Director | A | — | — |
| 2025-03-31 | Judy Krandel | Chief Financial Officer | A | — | — |
| 2025-01-03 | Joseph Michael Harris | Director | A | — | — |
| 2025-01-03 | Arthur H Amron | Director | A | — | — |
| 2025-01-03 | Alisa Lask | Director | A | — | — |
| 2025-01-03 | Oliver J. Spandow | Director | A | — | — |
| 2024-05-30 | Arthur H Amron | Director | Buy | — | — |
| 2024-05-16 | Arthur H Amron | Director | A | — | — |
| 2024-05-16 | Robert R. Jr. Banks | President and CEO | Buy | — | — |
| 2024-05-16 | Alisa Lask | Director | A | — | — |
| 2024-05-16 | Oliver J. Spandow | Director | A | — | — |
| 2024-05-16 | Joseph Michael Harris | Director | A | — | — |
| 2024-03-14 | Arthur H Amron | Director | MIXED | — | — |
| 2024-03-14 | CHARLES E DAVIDSON | 10%+ Owner | J | — | — |
| 2023-12-15 | Arthur H Amron | Director | A | — | — |
| 2023-12-15 | Joseph Michael Harris | Director | A | — | — |
| 2023-12-15 | Alisa Lask | Director | A | — | — |
| 2023-12-15 | Oliver J. Spandow | Director | A | — | — |
| 2023-12-11 | Robert R. Jr. Banks | President and CEO | Buy | — | — |
| 2023-11-03 | Judy Krandel | Chief Financial Officer | A | — | — |
| 2023-08-15 | Robert R. Jr. Banks | President and CEO | Buy | — | — |
| 2023-01-09 | Tom Gwydir | Director | A | — | — |
| 2023-01-09 | Joseph Michael Harris | Director | A | — | — |
| 2023-01-09 | Alisa Lask | Director | A | — | — |
| 2023-01-09 | Oliver J. Spandow | Director | A | — | — |
| 2023-01-09 | Arthur H Amron | Director | A | — | — |
| 2022-09-08 | Joseph Michael Harris | Director | A | — | — |
| 2022-03-07 | Andrew Astor | President, CEO & CFO | M | — | — |
| 2022-02-18 | Wesley S. Lobo | Chief Marketing Officer | F | — | — |
| 2021-12-16 | Oliver J. Spandow | Director | A | — | — |
| 2021-12-16 | Arthur H Amron | Director | A | — | — |
| 2021-12-16 | Tom Gwydir | Director | A | — | — |
| 2021-12-16 | Andrew Astor | President & CEO | A | — | — |
| 2021-12-16 | Alisa Lask | Director | A | — | — |
| 2021-09-03 | Wesley S. Lobo | Chief Commercial Officer | A | — | — |
| 2021-08-23 | Wesley S. Lobo | Chief Marketing Officer | Buy | — | — |
| 2021-08-19 | Tom Gwydir | Director | Buy | — | — |
| 2021-08-18 | Andrew Astor | President & CEO | Buy | — | — |
| 2021-06-03 | JOSEPH JACOBS | Director | X | — | — |
| 2021-06-01 | Daron Evans | CEO Specialty Renal Products | F | — | — |
| 2021-05-25 | Daron Evans | CEO of Specialty Renal Product | X | — | — |
| 2021-02-18 | Wesley S. Lobo | Chief Marketing Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,650,529 | — |
| — | 10%+ Owner | 3,600,552 | — |
| — | President and CEO | 190,000 | — |
| — | CEO Specialty Renal Products | 143,162 | — |
| — | Director | 138,456 | — |
| — | Director | 122,881 | — |
| — | Director | 97,795 | — |
| — | President, CEO & CFO | 92,773 | — |
| — | Chief Financial Officer | 68,861 | — |
| — | Director | 53,968 | — |
| — | Director | 48,629 | — |
| — | Director | 43,226 | — |
| — | Chief Marketing Officer | 35,168 | — |
| — | Director | 17,693 | — |
| — | Director | 3,448 | — |
| — | Director | 3,196 | — |
| — | Director | 1,622 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NEPH quote page; the site-wide leaderboard is on the insider transactions hub.